AMCMRAdvances in Modern Chinese Medicine Research3068-06383068-0646Art and Technology10.61369/AMCMR.202502013ArticleClinical Observation of Influence of Shibaweikeziliniaowan on Inflammatory Cytokines in Type 2 Diabetic Kidney Diseasehttps://artdesignp.com/journal/AMCMR/1/2/10.61369/AMCMR.202502013PengCong,ZhangWenchang,DaiLijun,qingDe,lamuCiren,zhenBian2025122025-06-20Objective: To evaluate the impact of Shibaweikeziliniaowan on inflammatory cytokine profiles in patients with type 2 diabetic kidney disease (DKD). Methods: Sixty DKD patients were randomized equally into a control group (n=30) and a treatment group (n=30). Both cohorts received standard care and oral Dapagliflozin. The treatment group additionally received Shibaweikeziliniaowan. The intervention lasted eight weeks. Parameters measured pre- and post-treatment included urine microalbumin (mA1b), Urinary Albumin Creatinine Ratio (UACR), glycosylated hemoglobin A1c (HbA1c), tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1). Results: Post-treatment, both groups exhibited significant reductions in mA1b, UACR, TNF-α, and IL-1 levels (P < 0.05, P < 0.01). Inter-group comparisons revealed statistically significant differences favoring the treatment group (P < 0.05). Conclusion: Shibaweikeziliniaowan demonstrates efficacy in lowering inflammatory cytokines, suggesting a renal protective role in DKD management.Type 2 diabetes mellitus (T2DM),Diabetic kidney disease (DKD),Shibaweikeziliniaowan,Inflammation,Tibetan medicine,Dapagliflozin

[1] Li Y, Teng D, Shi X, et al., 2020, Prevalence of Diabetes Recorded in Mainland China using 2018 Diagnostic Criteria from the American Diabetes Association: National Cross Sectional Study. BMJ, 2020(369): 997. [2] American Diabetes Association, 2020, 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes 2020. Diabetes Care, 2020(43): 135–151. https://doi.org/10.2337/dc20-S011 [3] Wu CC, Sytwu HK, Lin YF, 2012, Cytokines in Diabetic Nephropathy. Advances in Clinical Chemistry, 56(1): 55–74. [4] Chinese Society of Diabetesology, 2021, Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition). Chinese Journal of Diabetes, 13(4): 315–409. [5] Packer M, Anker SD, Butler J, et al., 2020, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine, 383(15): 1413–1424. [6] Neal B, Perkovic V, Mahaffey KW, et al., 2017, Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377(7): 644–657. [7] Perkovic V, Jardine MJ, Neal B, et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380(24): 2295–2306. [8] Heerspink HJL, Stefansson BV, Correa-Rotter R, et al., 2020, Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383(15): 1436–1446. [9] Luo GF, Zhang XF, 2008, Determination of Berberine Hydrochloride Content in Shibaweikeziliniaowan by HPLC Method. Qinghai Medical Journal, 38(8): 3. [10] Zheng LL, Wang G, Wu Q, 2023, The Protective Effect of Shibaweikeziliniaowan on the Kidneys of Diabetic Nephropathy Rats. Chinese Traditional Patent Medicine, 45(1): 264–267. [11] Liu AH, 2022, The Clinical Efficacy of the Shibaweikeziliniaowan in the Treatment of Diabetic Nephropathy. Journal of Medicine & Pharmacy of Chinese Minorities, 28(3): 24–25. [12] Suonancuo, 2019, The Clinical Application Value of the Shibaweikeziliniaowan in the Treatment of Diabetes in Tibetan Medicine. World Latest Medicine Information, 19(56): 227–228. [13] Liang PY, Yin LJ, Huaqiansangduo, et al., 2016, The Effect of Shibaweikeziliniaowan of Tibetan Medicine on Blood Sugar in Rats with High-Altitude Diabetes. Journal of Baotou Medical College, 32(12): 3–5. [14] Peng C, Gao MS, Kong CX, et al., 2016, Clinical Observation of Influence of Yuquanwan Decoction on Inflammatory Cytokines in Type 2 Diabetic Kidney Disease. Journal of Nanjing University of Traditional Chinese Medicine, 32(2): 3. [15] Purwata TE, 2011, High TNF-alpha Plasma Levels and Macrophages iNOS and TNF-alpha Expression as Risk Factors for Painful Diabetic Neuropathy. Journal of Pain Research, 4(1): 169–175. [16] Vesey DA, Cheung C, Cuttle L, et al., 2002, Interleukin-1β Stimulates Human Mediators of Inflammation Renal Fibroblast Proliferation and Matrix Protein Production by means of a Transforming Growth factor-β-dependent Mechanism. Journal of Laboratory and Clinical Medicine, 2002(140): 342–350.